PRESS RELEASES

Year
December 23 | 2024
RAPT Therapeutics Announces $150 Million Private Placement
December 23 | 2024
RAPT Therapeutics Announces $150 Million Private Placement
December 23 | 2024
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
November 12 | 2024
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
November 11 | 2024
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
August 08 | 2024
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
May 09 | 2024
RAPT Therapeutics Reports First Quarter 2024 Financial Results
April 09 | 2024
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
March 07 | 2024
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 05 | 2024
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
February 20 | 2024
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
February 13 | 2024
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
January 31 | 2024
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 02 | 2024
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference